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he interaction of cells with the extracellular matrix
(ECM) form of ﬁbronectin (FN) triggers changes in
growth, migration, and cytoskeletal organization that
differ from those generated by soluble FN. As cells deposit
and remodel their FN matrix, the exposure of new epitopes
may serve to initiate responses unique to matrix FN. To
determine whether a matricryptic site within the III1 module
of FN modulates cell growth or cytoskeletal organization, a
recombinant FN with properties of matrix FN was constructed
by directly linking the cryptic, heparin-binding COOH-
terminal fragment of III1 (III1H) to the integrin-binding III8–10
 
modules (glutathione-
 
S
 
-transferase [GST]–III1H,8–10). GST–
III1H,8–10 speciﬁcally stimulated increases in cell growth
T
 
and contractility; integrin ligation alone was ineffective. A
 
construct lacking the integrin-binding domain (GST–
III1H,2–4) retained the ability to stimulate cell contraction,
but was unable to stimulate cell growth. Both GST–
III1H,2–4 and matrix FN colocalized with caveolin and
fractionated with low-density membrane complexes by a
mechanism that required heparan sulfate proteoglycans.
Disruption of caveolae inhibited the FN- and III1H-mediated
increases in cell contraction and growth. These data sug-
gest that a portion of ECM FN partitions into lipid rafts
 
and differentially regulates cytoskeletal organization and
growth, in part, through the exposure of a neoepitope
within the conformationally labile III1 module.
 
Introduction
 
Fibronectins are a family of multidomain glycoproteins that
are deposited in the extracellular matrix (ECM)* where they
promote adhesive and migratory events (Hynes, 1990). The
polymerization of soluble fibronectin (FN) into insoluble
fibrils within the ECM is a dynamic, cell-dependent pro-
cess that is mediated by a series of events involving the ac-
 
tin cytoskeleton  and integrin receptors (Magnusson and
Mosher, 1998). Studies indicate that the interaction of cells
with the ECM form of FN triggers changes in cell cycle
progression,  cell migration, and cytoskeletal organization
that differ from those generated by the interaction of cells
with nonpolymerized FN (Morla et al., 1994; Sottile et al.,
1998; Sechler and Schwarzbauer, 1999; Hocking et al.,
2000). Other studies suggest that FN polymers formed in vitro
have antimetastatic (Pasqualini et al., 1996) and antiangiogenic
properties (Yi and Ruoslahti, 2001). The mechanism by which
the ECM form of FN gives rise to cellular phenotypes distinct
from soluble FN is not known.
Current models of FN matrix assembly propose that binding
of soluble FN to the cell surface triggers a series of conforma-
tional changes that result in the exposure of homophilic
binding sites and the subsequent elongation of FN fibrils
(Magnusson and Mosher, 1998). The first type III module
of FN (III1) contains a binding site for the NH
 
2
 
 terminus of
FN that is not exposed within soluble FN (Hocking et al.,
1994), but may become exposed on cell surfaces during FN
polymerization (Zhong et al., 1998; Tellier et al., 2000).
Moreover, proteolytic cleavage of III1 at Ile597 exposes a
cryptic heparin-binding activity in III1 (Litvinovich et al.,
1992). These data suggest the possibility that during FN poly-
merization, a “matricryptic” (Davis et al., 2000), heparin-
binding activity is exposed in III1, which serves to trigger
cellular responses that are unique to ECM FN.
Previous work has shown that FN stimulates cell growth
(Sottile et al., 1998) and contractility (Hocking et al., 2000)
by a mechanism that requires the polymerization of FN into
the ECM. To construct a recombinant FN with properties
 
of matrix FN, we engineered a glutathione-
 
S
 
-transferase
(GST)– tagged fusion protein in which the cryptic, heparin-
binding III1 fragment (III1H) was linked directly to the inte-
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grin-binding III8–10 modules (GST–III1H,8–10). FN-null
(FN
 
 
 
/
 
 
 
) cells, which do not produce FN and are grown un-
der serum-free conditions (Sottile et al., 1998), were used in
conjunction with recombinant FN fragments to eliminate
any effects of endogenous FN or FN fragments. Our data in-
dicate that treatment of FN
 
 
 
/
 
 
 
 cells with GST–III1H,8–10
stimulates a specific increase in cell growth and contractility.
A construct in which the III2–4 modules were substituted for
the integrin-binding III8–10 modules (GST–III1H,2–4) re-
tained the ability to stimulate cell contraction, but did not
stimulate cell growth. Both GST–III1H,2–4 and polymer-
ized FN colocalized with caveolin and fractionated with low-
density membrane complexes by a mechanism that required
heparan sulfate proteoglycans (HSPGs). Treatment of cells
with sterol-binding compounds to disrupt caveolae blocked
the localization of GST–III1H,2–4 and FN to lipid rafts and
inhibited the increase in cell contraction and growth induced
by either FN or the III1H-containing constructs. These data
suggest that a portion of ECM FN partitions into lipid rafts
and differentially regulates cytoskeletal organization and cell
growth, in part, through the exposure of a neoepitope within
the conformationally labile III1 module.
 
Results
 
A cryptic fragment of III1 stimulates cell growth
 
In the absence of FN, FN
 
 
 
/
 
 
 
 cells that are adherent to type I
collagen exhibit a typical cell doubling rate of 20 h (Sottile et
al., 1998). Addition of GST–III1H,8–10 to collagen-adher-
ent FN
 
 
 
/
 
 
 
 cells stimulated a dose-dependent increase in cell
growth compared with untreated cells (Fig. 1 A). Substitu-
tion of the heparin-binding III13 module (Bloom et al.,
1999) for III1H (GST–III8–10,13) did not stimulate cell
growth (Fig. 1 A). Treatment of cells with an FN construct
in which the III2–4 modules were substituted for the III8–
10 modules also did not increase cell growth (Fig. 1 A), sug-
gesting that integrin ligation is necessary for the growth re-
sponse to GST–III1H,8–10. However, treatment of cells
with integrin-binding constructs in which the III1H frag-
ment was absent (GST–III8–10 and GST–III9–10), or in
which the corresponding COOH-terminal III2 fragment
(III2H) was substituted for III1H (GST–III2H,8–10) failed
to increase cell growth (Fig. 1 B), suggesting that III1H is
also required. Cell growth was not increased when individu-
ally expressed GST–III1H was added to cells either alone or
in combination with GST–III8–10 (GST–III1H 
 
 
 
 GST–
III8–10; Fig. 1 B), suggesting that clustering of cell surface–
bound III1H by binding of III8–10 to integrin receptors
(Hynes, 1990) may be important for its activity.
To further define the role of III1H, FN
 
 
 
/
 
 
 
 cells were
treated with GST–III1H,8–10 in the absence and presence of
increasing concentrations of GST–III1H. As shown in Fig. 2
A, GST–III1H,8–10-stimulated growth was inhibited by co-
incubation of cells with the III1H fragment. In contrast,
GST–III1H,8–10-stimulated growth was not inhibited when
cells were coincubated with the fragment of III2 correspond-
ing to the III1H truncation (GST–III2H; Fig. 2 A). GST–
III1H,8–10-stimulated growth was also inhibited by addition
of the integrin-binding constructs GST–III8–10 and GST–
III9–10 (Fig. 2 B). Moreover, mutation of the integrin syn-
 
ergy site (GST–III9–10
 
R1374,1379A
 
) (Aota et al., 1994) sup-
pressed the ability of GST–III9–10 to inhibit GST–III1H,8–
10 growth (Fig. 2 B), further demonstrating a role for integrin
ligation in the growth response to GST–III1H,8–10.
 
Heparin-binding activity is required for increased growth
 
The ability of GST–III1H,8–10 to bind to heparin was as-
sessed in solid phase binding assays. As shown in Fig. 3 A,
GST–III1H,8–10 bound biotin-labeled heparin, whereas
GST–III8–10 did not. Heparin-binding activity was also
observed with GST–III8–10,13 and was greater than that
observed with GST–III1H,8–10 (Fig. 3 A). The heparin-
binding activity of GST–III8–10,13 was similar to that ob-
served with the FN construct that contains both the III12
and III13 modules (GST–III12–13) (Fig. 3 A). Control
studies indicated that an equal amount of fusion protein
bound in each well (unpublished data).
To determine whether the heparin-binding activity of III1H
plays a role in GST–III1H,8–10-stimulated growth, cells were
incubated with GST–III1H,8–10 in the absence and presence
of either sulfated or nonsulfated heparin. Coincubation with
sulfated heparin, but not nonsulfated heparin, reduced GST–
III1H,8–10 growth to control levels (Fig. 3 B). Similarly, treat-
ment with heparinase I inhibited the growth response to GST–
III1H,8–10 by 
 
 
 
50%, suggesting a role for HSPGs (Fig. 3 C).
Heparinase treatment had no effect on control cell growth
(Fig. 3 C). To determine whether other known heparin-bind-
Figure 1. Effect of GST–III1H,8–10 on cell growth. FN
 /  cells 
were seeded on collagen-coated wells. 4 h after seeding, cells were 
treated with increasing concentrations of either intact FN ( Fn,  ), 
GST–III1H,8–10 ( ), GST–III1H,2–4 ( ), or GST–III8–10,13 ( ). In 
B, cells were treated with 250 nM of the various recombinant proteins. 
4 d after seeding, cell number was determined as described in the 
Materials and methods. Data are presented as fold increase in cell 
number over control (growth in the absence of additional protein). 
*Significantly different from control, P   0.001. 
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ing domains could compete with the growth-promoting effects
of GST–III1H,8–10, FN
 
 
 
/
 
 
 
 cells were incubated with GST–
III1H,8–10 in the absence and presence of various heparin-
binding fragments. As shown in Fig. 3 D, addition of a 10-fold
excess of either GST–III1H, GST–III12–13, or GST–Vn-
HBD inhibited the cell growth response to GST–III1H,8–10.
In contrast, addition of the NH
 
2
 
-terminal 70-kD fragment
had little effect on GST–III1H,8–10-stimulated growth. Ad-
dition of the heparin-binding domains to control cells had no
effect on basal cell growth (Fig. 3 D). Taken together, these
data suggest that the heparin-binding activity of III1 is neces-
sary for the stimulation of cell growth.
 
Effect of III1H on cell contractility
 
FN polymerization has also been shown to trigger cytoskele-
tal tension generation (Hocking et al., 2000). To determine
the role of III1H in cell contractility, FN
 
 
 
/
 
 
 
 cells were im-
bedded in floating collagen gels in the absence and presence
of increasing concentrations of either intact FN or the vari-
ous fusion proteins. GST–III1H,8–10 stimulated an in-
crease in cell contractility to a similar extent as that observed
with intact FN (Fig. 4 A). Furthermore, in contrast to the
negative results obtained in the growth studies, treatment of
cells with GST–III1H,2–4 also promoted a significant in-
crease in collagen gel contraction (Fig. 4 A). As with the
growth assays, substitution of the heparin-binding III13
module for III1H (GST–III8–10,13) failed to stimulate col-
lagen gel contraction (Fig. 4 A). Addition of the III1H frag-
ment resulted in a dose-dependent inhibition of GST–
III1H,8–10-induced contraction; intact III1 had no effect
(Fig. 4 B). Moreover, treatment of cells with GST–III1–4,
in which III1H was replaced with the intact III1 module,
did not stimulate contraction (Fig. 4 C), suggesting that ex-
posure of cryptic residues within III1 is required to induce
cytoskeletal tension generation. Constructs in which one or
more of the COOH-terminal type III modules were deleted
(GST–III1H,2–3, GST–III1H,2, and GST–III1H) did not
stimulate cell contractility (Fig. 4 C), suggesting that sec-
ondary sequences contribute to the ability of III1H to stim-
ulate contraction. These data suggest that a cryptic, heparin-
binding region within the III1 module of FN plays a unique
role in modulating both cell contractility and growth.
 
GST–III1H,8–10 does not localize to focal contacts
 
To explore the mechanism by which the III1H constructs
stimulate growth and contractility, studies were conducted
to determine whether GST–III1H,2–4 and GST–III1H,8–
10 localize to specific cell surface structures. Collagen-adher-
ent FN
 
 
 
/
 
 
 
 cells were treated with the various fusion proteins
and then examined by immunofluorescence microscopy for
GST to visualize the fusion proteins, and for vinculin, a
marker of focal adhesions (Jockusch et al., 1995). As shown
in Fig. 5, staining of GST–III1H,2–4 (Fig. 5 A, arrow) and
GST–III1H,8–10 (Fig. 5 B, arrow) was detected in discrete
clusters that did not colocalize with vinculin (Fig. 5, E and
F). In contrast, GST–III8–10,13 staining strongly colocal-
ized with vinculin (Fig. 5, C, G, and K, arrows) in a pattern
similar to that observed with GST–III8–10 (unpublished
Figure 2. Role of III1H and III9–10 in GST–III1H,8–10-stimulated 
growth. FN
 /  cells were seeded as in the legend to Fig. 1. In A, 
cells were treated with 250 nM GST–III1H,8–10 in the absence (0) 
and presence of GST–III1H or 1  M GST–III2H. * GST–III1H (1  M) 
differs significantly from  GST–III2H, P   0.01. In B, cells were treated 
with 100 nM GST–III1H,8–10 in the absence (control) and presence of 
either 1  M GST–III8–10, GST–III9–10, or GST–III9–10
R1374,1379A. Cells 
were processed as indicated in the legend to Fig. 1. * GST–III9–
10
R1374,1379A differs significantly from  GST–III9–10, P   0.01.
Figure 3. Role of heparin-binding activity in GST–III1H,8–10 
growth. (A) Glutathione-coated plates were incubated with 
saturating concentrations of the various fusion proteins. Binding of 
biotin–heparin was assayed by EIA. Data represent the mean 
absorbance of triplicate wells   SD. In B–D, Fn
 /  cells were 
seeded as indicated in the legend to Fig. 1. After 4 h, cells were 
treated with 100 nM GST–III1H,8–10 or an equal volume of PBS. 
In B, cells were coincubated with 50  M sulfated (heparin I-S) or 
nonsulfated (heparin IV-A) heparin. *Significantly different from 
 GST–III1H,8–10, P   0.001. In C, cells were pretreated with 
heparinase I or an equal volume of DME. *Significantly different 
from  GST–III1H,8–10, P   0.05. In D, cells were coincubated 
with 1  M of the various heparin-binding fragments. *Significantly 
different from GST–III1H,8–10 alone, P   0.001. 
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data). No staining was observed when cells were treated with
GST alone (Fig. 5 D).
 
GST–III1H,2–4 colocalizes with caveolin by an 
HSPG-dependent mechanism
 
To further identify the structures in which the III1H con-
structs localized, cells were incubated with either GST–
III1H,2–4 or GST and examined by immunofluorescence
microscopy for GST and caveolin, a marker of cell surface
membrane invaginations, termed caveolae (Anderson, 1998).
 
As shown in Fig. 6, GST–III1H,2–4 staining (Fig. 6 A, ar-
rows) colocalized with caveolin staining (Fig. 6, B and C, ar-
rows). When cells were treated with GST alone, GST staining
was not observed (Fig. 6 D), whereas caveolin staining was
still detected (Fig. 6 E, arrow). Pretreatment of cells with
filipin III, which binds cholesterol and disrupts caveolae (An-
derson, 1998), caused a concomitant decrease in both GST–
III1H,2–4 and caveolin staining (Fig. 6, G and H). Filipin III
did not disrupt cell adhesion, as cells treated with filipin III re-
mained well spread (Fig. 6 I).
To determine whether the cell surface localization of GST–
III1H,2–4 was dependent upon HSPGs, collagen-adherent
FN
 
 
 
/
 
 
 
 cells were pretreated with heparinase before the addition
of GST–III1H,2–4. As shown in Fig. 7 A, clustering of GST–
III1H,2–4 on the cell surface was abolished by pretreatment
with heparinase. In contrast, pretreatment of cells with either
chondroitinase ABC (Fig. 7 a, C) or neuraminidase (Fig. 7 a,
D) had no effect on the cell surface staining of GST–III1H,2–4.
Heparinase treatment did not affect cell adhesion, as demon-
strated by vinculin staining of focal adhesions (Fig. 7 a, F).
Proteins associated with caveolae are resistant to solubiliza-
tion by either Triton X-100 or high pH carbonate buffer and
can be purified by flotation on sucrose gradients (Schwab et
al., 2000). To determine whether GST–III1H,2–4 associates
with low-density membrane complexes by a mechanism that
is dependent upon HSPGs, collagen-adherent FN
 
 
 
/
 
 
 
 cells
Figure 4. GST–III1H,2–4 stimulates cell contraction. FN
 /  cells 
were mixed with neutralized type I collagen in the presence of (A) 
increasing concentrations of intact FN ( Fn,  ), GST–III1H,8–10 
( ), GST–III1H,2–4 ( ), or GST–III8–10,13 ( ). *Significantly 
different from contraction in the absence of additional protein, 
P   0.001. In B, 250 nM GST–III1H,8–10 was added to gels in the 
absence (0) and presence of increasing concentrations of III1H or 1 
 M III1. *The addition of III1H (1.1  M) is significantly different 
from  III1, P   0.01. In C, 250 nM fusion protein or an equal 
volume of PBS was added to cells. *Significantly different from 
 PBS, P   0.001. Cell–collagen mixtures were polymerized as 
described in the Materials and methods.
Figure 5. Localization of III1H constructs on cell surfaces. 
Collagen-adherent Fn
 /  cells were incubated with 250 nM of GST–
III1H,2–4 (A, E, and I), GST–III1H,8–10 (B, F, and J), GST–III8–10,13 
(C, G, and K), or GST (D, H, and L). Cells were processed for 
immunofluorescence as indicated in the Materials and methods. Fusion 
proteins were visualized using a polyclonal anti-GST antibody 
followed by a Texas red–labeled goat anti–rabbit antibody (A–D). 
Vinculin was visualized using an antivinculin mAb followed by an 
FITC-labeled goat anti–mouse antibody (E–H). In the merged images 
shown in I–L, areas of colocalization appear yellow. Bar, 10  M. 
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were pretreated with heparinase I or an equivalent volume of
DME, before the addition of GST–III1H,2–4. Cells were ex-
tracted with 1% Triton X-100 and fractionated by high-speed
centrifugation. Under these conditions, the majority of cellu-
lar protein remains associated with the high-density sucrose
(Fig. 7 b, fractions 9–12); proteins associated with low-density
lipids are buoyant and rise to the interface of the 5 and 30%
sucrose layers (Schwab et al., 2000). As previously demon-
strated, both caveolin and 
 
 
 
-actin, but not LAMP-1, associate
with low-density membrane domains and thus migrate to the
interface of the 5 and 30% sucrose layers (Fig. 7 b, fractions 5
and 6) (Anderson, 1998). GST–III1H,2–4 also comigrated to
these low-density membrane fractions (Fig. 7 b, fractions 5
and 6). Moreover, pretreatment of cells with heparinase sig-
nificantly reduced the amount of GST–III1H,2–4 associated
with the low-density lipid complexes (Fig. 7 b). In contrast,
heparinase treatment had no effect on the association of either
caveolin or 
 
 
 
-actin with low-density lipid complexes (Fig. 7
b). These data suggest that GST–III1H,2–4 localizes to cave-
olin-enriched membrane domains by an HSPG-dependent
mechanism. GST–III1H,8–10 was also detected in the caveo-
lin-enriched fractions, whereas GST–III8–10,13 was not (Fig.
7 c), providing further evidence that III1H mediates the local-
ization of these FN fragments to lipid rafts.
 
Partitioning of FN to lipid rafts requires FN 
polymerization and HSPGs
 
To determine whether intact FN also colocalizes with caveo-
lin, confluent FN
 
 
 
/
 
 
 
 cells were incubated with FN for 4 h.
Cells were costained for FN and caveolin. As demonstrated in
Fig. 8 a, areas of FN (Fig. 8 a, A, arrow) and caveolin (Fig. 8 a,
Figure 6. Colocalization of GST–III1H,2–4 with caveolin. 
Collagen-adherent FN
 /  cells were incubated with 250 nM of GST 
(D, E, and F) or GST–III1H,2–4 in the absence (A, B, and C) and 
presence of 2.5  g/ml filipin III (G, H, and I). Cells were then processed 
for immunofluorescence. Fusion proteins were visualized using an 
anti-GST mAb followed by an FITC-labeled goat anti–mouse antibody 
(A, D, and G). Caveolin was visualized using a polyclonal anticaveolin 
antibody followed by a Texas red–labeled goat anti–rabbit antibody 
(B, E, and H). In the merged images shown in C and F, areas of 
colocalization appear yellow. The phase contrast image of cells 
treated with GST–II-1H,2–4 and filipin III is shown in I. Bar, 10  M.
Figure 7. Effect of heparinase on the localization of GST–III1H2–4 
to caveolin-enriched lipid rafts. (a) Collagen-adherent FN
 /  cells 
were pretreated with either heparinase I (B and F), chondroitinase 
ABC (C and G), neuraminidase (D and H), or an equal volume of 
DME (A and E) before the addition of 250 nM GST–III1H,2–4. 
Staining for GST (A–D) and vinculin (E–H) was conducted as in the 
legend to Fig. 5. Bar, 10  M. (b) Confluent Fn
 /  cells were treated 
with either heparinase I or DME, before the addition of 250 nM 
GST–III1H,2–4. (c) Cells were incubated with 250 nM GST–
III1H,8–10 or GST–III8–10,13. Cell lysates were fractionated by 
sucrose density gradient centrifugation, as described in the Materials 
and methods. Aliquots (120  l) of each fraction were analyzed by 
PAGE and immunoblotting. GST–III1H,2–4 was identified using 
anti-FN mAb clone CCBD that recognizes an epitope in III4. The 
blot was then stripped and reprobed for LAMP-1. A separate 
immunoblot containing 5  l of each fraction was analyzed for 
caveolin followed by  -actin. GST–III1H,8–10 and GST–III8–10,13 
were identified using an anti-GST monoclonal antibody. Molecular 
mass markers are indicated to the left. 
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B, arrow) were found to colocalize (Fig. 8 a, C, arrow), partic-
ularly along cell edges. In addition, discrete areas of FN fibril
staining appeared to terminate at areas enriched with caveolin
(arrowhead). To determine whether the localization of FN
to caveolin-enriched lipid rafts is similarly dependent on
HSPGs, FN
 
 
 
/
 
 
 
 cells were pretreated with heparinase before
incubation with FN. After 5 h, cells were extracted with 1%
Triton X-100 and fractionated. As shown in Fig. 8 b, a por-
tion of the FN from untreated cells migrated to the caveolin-
enriched fractions (fractions 5 and 6). Pretreatment of cells
Figure 8. Localization of FN to caveolin-enriched domains. 
(a) Vitronectin-adherent FN
 /  cells were incubated with 40 nM FN 
for 5 h. FN was visualized using a monoclonal anti-FN antibody 
followed by an FITC-labeled goat anti–mouse antibody (A). Caveolin 
staining is shown in B. The merged image appears in C. Bar, 10  M. 
(b) Confluent FN
 /  cells were treated with heparinase III or an 
equal volume of DME for 1 h followed by 40 nM FN for an 
additional 5 h. Cells were extracted with 1% Triton X-100 and 
analyzed by sucrose density gradient centrifugation followed by 
immunoblotting for either FN (120  l fraction/lane) or caveolin 
(5  l fraction/lane). (c) Confluent FN
 /  cells were treated for 18 h 
with 20 nM FN in the presence of either nonimmune mouse IgG or 
9D2 IgG. Cells were extracted with sodium carbonate buffer and 
fractionated by sucrose density gradient centrifugation. Aliquots of 
each fraction were analyzed by PAGE and immunoblotting using 
anti-FN and anticaveolin antibodies. (d) FN-null cells were incubated 
with 20 nM FN for 18 h and then incubated in the absence (0) or 
presence of either 5 or 10 mM cyclodextrin for 2 h. Cell extracts 
were separated by sucrose density gradient centrifugation and 
fractions 5 and 6 (corresponding to the low-density lipid fractions) 
were combined. Aliquots of both the combined fractions and 
fraction 12 (Triton X-100 soluble) were analyzed for FN by 
immunoblotting. Molecular mass markers are indicated to the left.
with heparinase significantly reduced the amount of FN asso-
ciated with these fractions (Fig. 8 b, fractions 5 and 6).
To determine whether the localization of FN to caveolin-
enriched lipid rafts requires FN polymerization, FN-null
cells were treated with FN in the presence of either control
mouse IgG or the anti-FN mAb, 9D2. The 9D2 mAb rec-
ognizes an epitope within the III1 module of FN and inhib-
its FN polymerization, but does not block the initial associa-
tion of soluble FN with cell surfaces (Chernousov et al.,
1991). After an 18-h incubation, cells were extracted using a
high pH carbonate buffer and fractionated. As shown in Fig.
8 c, when FN polymerization was inhibited by the 9D2
mAb, FN staining was not detected in the low-density frac-
tions (Fig. 8 c, fractions 5–8).
 -Cyclodextrin removes cholesterol from cell membranes
and alters the association of proteins with caveolae (Keller
and Simons, 1998). To determine whether disruption of ca-
veolae would disrupt the association of FN with low-density
lipid rafts, cells were allowed to polymerize an FN matrix
and then were treated with cyclodextrin for 2 h. As shown in
Fig. 8 d, cyclodextrin preferentially removed the FN associ-
ated with the low-density lipid fractions (fractions 5 and 6);
cyclodextrin had no effect on the interaction of nonlipid-asso-
ciated FN with cells (Fig. 8 d, fraction 12). Taken together,
these data indicate that a portion of matrix FN partitions to
lipid rafts by a mechanism that requires HSPGs.
III1H-mediated growth and contractility are inhibited 
by sterol-binding agents
To determine whether the fraction of GST–III1H,2–4 and
FN that associates with caveolae is biologically active, Fn
 / 
cells were pretreated with the cholesterol-binding com-
pounds nystatin and filipin III. Cells were then embedded in
collagen gels in the presence of either FN or GST–III1H,2–4
and collagen gel contraction was assessed. As demonstrated
in Fig. 9 A, pretreatment of cells with nystatin inhibited the
contraction induced by GST–III1H,2–4 and partially inhib-
ited the contraction induced by FN. In contrast, basal con-
traction was not altered by nystatin treatment (Fig. 9 A). A
similar inhibition profile was obtained when cells were pre-
treated with filipin III (Fig. 9 B).
Studies were also conducted to determine whether dis-
ruption of caveolae inhibits GST–III1H,8–10- and FN-
induced cell growth. Pretreatment of cells with nystatin
inhibited the increase in cell growth induced by GST–
III1H,8–10 and partially inhibited the increase in cell
growth induced by intact FN (Fig. 9 C). Nystatin did not
significantly affect basal cell growth (Fig. 9 C,  PBS). Pre-
treatment of cells with cyclodextrin also inhibited GST–
III1H,8–10- and FN-stimulated growth while having no ef-
fect on basal growth (Fig. 9 D). Taken together, these data
suggest that the ability of the heparin-binding fragment of
III1 to stimulate cell contractility and growth is dependent
upon its localization to caveolin-containing lipid rafts.
Discussion
Although the ECM form of FN is thought to be the primary
functional form in vivo (Hynes, 1990), studies to date have
focused primarily on the effects of soluble FN on cell func- A cryptic fibronectin fragment stimulates growth | Hocking and Kowalski 181
tion. Recent studies indicate that the interaction of cells with
matrix FN triggers changes in cell behavior that are distinct
from those generated by the interaction of cells with soluble
FN (Morla et al., 1994; Sottile et al., 1998; Sechler and
Schwarzbauer, 1999; Hocking et al., 2000). The ability of
FN constructs containing the cryptic heparin-binding re-
gion of III1 to stimulate cell growth and contractility sug-
gests that one mechanism by which matrix FN gives rise to
distinct cellular phenotypes is through the exposure of a
neoepitope within III1 during FN matrix deposition or re-
modeling. Both the III1H-containing constructs, as well as
intact FN, colocalized with caveolin and fractionated with
caveolin-enriched membrane domains by a mechanism that
required HSPGs. Moreover, localization of FN to caveolin-
enriched fractions was blocked by an inhibitor of FN poly-
merization, suggesting that the matrix form of FN specifi-
cally translocates to lipid rafts. In addition, disruption of
caveolae inhibited both the localization and the cellular re-
sponses to the III1H constructs and intact FN. Taken to-
gether, these data suggest that during ECM remodeling, a
portion of matrix FN partitions into lipid rafts and differen-
tially regulates cytoskeletal organization and cell growth, in
part, through the exposure of a matricryptic, heparin-bind-
ing site within the III1 module.
The loss of lipid-associated FN upon treatment of cells
with the inhibitor of FN polymerization, 9D2 mAb (Cher-
nousov et al., 1991), suggests that the association of FN with
lipid rafts occurs as FN is either assembled or remodeled
within the ECM. Furthermore, the cholesterol-binding
compound nystatin does not inhibit FN matrix deposition
(unpublished data). These data suggest that the formation of
an FN matrix does not depend on FN localization to lipid
rafts. Rather, these data indicate that as a consequence of FN
matrix deposition, a portion of the matrix FN translocates to
lipid rafts where it modulates cell function. In support of
this, previous work has shown that cell cycle progression is
altered in cells that have assembled a matrix consisting of an
FN construct in which modules III1–7 were deleted (Sechler
and Schwarzbauer, 1998).
Previous studies have demonstrated that treatment of cells
with an isolated fragment of III1, termed III1C (NH2 termi-
nus   Asn
600), inhibits lysophosphatidic acid–mediated ac-
tin organization and tyrosine phosphorylation (Bourdoulous
et al., 1998), decreases cell migration (Morla et al., 1994),
and inhibits tumor cell angiogenesis (Yi and Ruoslahti,
2001). The ability of III1C to affect cytoskeletal function
has been attributed to its ability to either disrupt preexisting
FN matrices (Bourdoulous et al., 1998) or to stimulate in-
creased FN matrix deposition (Yi and Ruoslahti, 2001), de-
pending upon its concentration. In the present study, the
III1H-mediated increases in cell growth and contraction oc-
curred in the absence of any endogenous FN. These results
indicate that, in addition to its ability to affect cellular events
by altering matrix composition, the III1 module of FN can
also directly affect cell function.
Sottile et al. (2000) recently demonstrated that HSPGs play
a role in the stimulation of cell growth induced by FN poly-
merization. Similarly, in the present study, the stimulation of
cell growth by GST–III1H,8–10 was inhibited by either hep-
arin or pretreatment of cells with heparinase. In addition, hep-
Figure 9. Effect of cholesterol-binding agents on cell growth and 
contraction. Fn
 /  cells were imbedded into collagen gels, as 
indicated in the legend to Fig. 4, in the presence of either 250 nM 
GST–III1H,2–4, 50 nM FN ( Fn), or an equal volume of PBS. In A, 
some gels received 50  g/ml nystatin. *Significantly different from 
the corresponding no addition, P   0.01. In B, some gels received 
filipin III or an equal volume of ethanol (EtOH). 
 Significantly 
different from  GST–III1H,2–4, P   0.01. *Significantly different 
from  GST–III1H,2–4, P   0.001. Collagen gels were cast and 
processed as indicated in the legend to Fig. 4. In C and D, collagen-
adherent, FN
 /  cells were treated with (C) 50  g/ml nystatin or 
(D) 2 mM cyclodextrin. Cells were then incubated with either 100 
nM of GST–III1H,8–10, 40 nM FN ( Fn), or an equal volume of 
PBS. 3 d after seeding, cells were processed as indicated in the 
legend to Fig. 1. *Significantly different from the corresponding no 
addition, P   0.01.182 The Journal of Cell Biology | Volume 158, Number 1, 2002
arinase inhibited the localization of both GST–III1H,2–4 and
intact FN to caveolae. These data suggest that HSPGs func-
tion as the cell surface receptor for the heparin-binding region
of III1 and further, that a similar HSPG-dependent mecha-
nism is involved in the partitioning of III1H and matrix FN
into caveolae. Previous studies have localized the stress fiber–
promoting activity of the COOH-terminal heparin-binding
domain of FN to III13 (Bloom et al., 1999). In the present
study, GST–III8–10,13 was unable to increase cell growth
or contraction and did not localize to caveolae. However,
addition of excess GST–III12–13 to cells inhibited GST–
III1H,8–10-stimulated growth, suggesting that III13 can
compete with III1H for binding to the glycosaminoglycan
chains of the HSPGs. Additional interactions, possibly involv-
ing the core protein of the HSPG (Woods, 2001), likely con-
tribute to the subsequent generation of distinct intracellular
signals that modulate cell growth and contraction.
The molecular processing of information received by cells
from their extracellular environment occurs in specific mem-
brane domains, including caveolae, focal adhesions, and areas of
cell–cell contact. Caveolae exist as cholesterol- and sphin-
golipid-enriched microdomains within the cell membrane and
play a key role in signal transduction events (Brown and Lon-
don, 1998). Several growth factor receptor tyrosine kinases as
well as nonreceptor signaling proteins, including Src family ki-
nases, MAPK, and PKC , have been shown to localize to cave-
olae (Brown and London, 1998). The ability of heparin-bind-
ing III1 FN fragments, as well as matrix FN, to partition to
caveolin-enriched microdomains represents a novel mechanism
by which signals derived from the ECM may be transmitted to
the interior of the cell to modulate growth and contractility.
During wound healing, migrating epithelial cells and fibro-
blasts deposit and remodel the ECM in order to support fur-
ther cell ingrowth and neovascularization (Clark, 1995). Un-
der normal circumstances, the synthesis of ECM proteins
gradually decreases during tissue repair (Clark, 1995). How-
ever, in the absence of appropriate inhibitory signals, the syn-
thetic phenotype of wound fibroblasts persists and can lead to
the development of fibrotic changes within tissues, including
excess deposition of FN, stimulation of fibroblast prolifera-
tion, and altered organization of collagen fibrils (Clark, 1995).
As such, the continuous or inappropriate exposure of the ma-
tricryptic, heparin-binding activity of FN’s III1 module may
contribute to the fibrotic phenotype by enhancing and/or
prolonging cell contraction and growth. Developing methods
to control the extent and/or duration of the exposure of cells
to matrix-specific epitopes may provide useful approaches to
promote normal wound healing and prevent fibrosis.
Materials and methods
Reagents
Human plasma FN was isolated from Cohn’s fraction I and II, as previously
described (Miekka et al., 1982). The NH2-terminal 70-kD FN fragment was
generated as previously described (Hocking et al., 1994). Vitronectin was
purified from fibrinogen-depleted human plasma (Hocking et al., 1999).
Unless otherwise indicated, chemical reagents were from Sigma-Aldrich.
Cell culture
Mouse embryo cells, derived from FN
 /  embryos and adapted to grow
under serum-free conditions (Sottile et al., 1998), were provided by Jane
Sottile (University of Rochester, Rochester, NY). FN
 /  cells were cultured
on collagen-coated dishes in a 1:1 mixture of Cellgro
® (Mediatech) and
Aim V (Life Technologies).
Recombinant FNs
Fig. 10 illustrates the FN constructs used in this study. PCR was used to
amplify human FN cDNA (a gift of Jean Thiery, Institut Curie, Paris,
France) encoding the following amino acids (Petersen et al., 1989): a
COOH-terminal fragment of the first type III module (III1H; bases 1802–
2032; Ile 597–Thr 673), III1H plus the III2 module (III1H,2; bases 1802–
2347; Ile 597–Thr 778), III1H plus the III2 and III3 modules (III1H,2–3;
bases 1802–2635; Ile 597–Asp 874), III1H plus the III2, III3, and III4 mod-
ules (III1H,2–4; bases 1802–2905; Ile 597–Thr 964), the full-length first
through fourth type III modules (III1–4; bases 1745–2905; Ser 578–Thr
964), a COOH-terminal fragment of the III2 module corresponding to the
III1H fragment (III2H; bases 2132–2347; Val 707–Thr 778), the 8–10th
type III modules (III8–10; bases 3716–4540; Ala 1326–Thr 1600), and the
III13 module (III13; bases 5357–5623; Asn 1873–Thr 1961). The sense
primer for III1H, III1H,2, III1H,2–3, and III1H,2–4 (5 -CCCGGATCCATC-
CAGTGGAATGCACCACAG-3 ), the sense primer for III1–4 (5 -CCC-
GGATCCAGTGGTCCTGTCGAAGTATTTAT-3 ), and the sense primer
for III2H (5 -CCCGGATCCGTCTCCTGGGTCTCAGCTTC-3 ) contain a
BamH1 site (shown in bold) at the 5  end. The sense primer for III8–10 and
III8–10,13 (5 -CCCAGATCTGCTGTTCCTCCTCCCACTGAC-3 ) includes a
BglII site. The sense primer for III13 (5 -CCCATCGATAATGTCAGCCCAC-
CAAGAAGG-3 ) includes a Cla site. The antisense primers for III1H (5 -
CCCGAATTCCTATGTGCTGGTGCTGGTGGTG-3 ), III1H,2 and III2H
(5 -CCCGAATTCCTATGTTGTTTGTGAAGTAGACAGG-3 ), III1H,2–3 (5 -
CCCGAATTCCTAATCTGAGCGTGGGGTGCCAG-3 ), and III1H,2–4 and
III1–4 (5 -CCCGAATTCCTAGGTTGTCTGTTGAGCAGTCAG-3 ) contain
an EcoRI site. The antisense primers for III8–10 (5 -CCCCCCGGGCTAT-
GTTCGGTAATTAATGGAAATTG-3 ) and III8–10,13 (5 -CCCCCCGGG-
CTAAGTGGAGGCGTCGATGACCAC-3 ) include a SmaI site. III1H,8–10
and III2H,8–10 were made by PCR amplification of either III1H or III2H
with BamHI sites at both the 5  and 3  ends. The sense primers used were
the same as those for III1H and III2H. The antisense primers for III1H (5 -
CCCGGATCCTGTGCTGGTGCTGGTGGTG-3 ) and III2H (5 -CCCG-
GATCCTGTTGTTTGTGAAGTAGACAGG-3 ) contain BamHI sites. The
III8–10 modules were PCR amplified with BglII and SmaI sites at the 5  and
3  ends, respectively. These restriction enzyme sites generate two addi-
tional amino acids (Gly and Ser) between either III1H or III2H and III8–10.
To construct III8–10,13, an antisense primer for III10 (5 -CCCATC-
GATAATGTCAGCCCACCAAGAAGC-3 ) was synthesized with a Cla site,
which generates two additional amino acids (Ile and Asp) between III10
and III13. The III9–10 synergy site mutant (GST/III9–10
R1374,1379A) was pro-
duced using the following mutant primers: 5 -GCGGTGCCCCACTCTGC-
GAATTCCATCACCCTC-3  (sense) and 5 -CGCAGAGTGGGGCACCG-
Figure 10. FN fusion proteins. Schematic representation of an FN 
subunit and recombinant GST fusion proteins. Relevant type III 
modules are numbered. A cryptic fibronectin fragment stimulates growth | Hocking and Kowalski 183
CATCTTCTCG-3  (antisense). The outer primers were the same as those
used to amplify nonmutant III9–10 (Hocking et al., 1999). The amplifica-
tion of III1, III9–10, III12–13, and the heparin-binding domain of vitronec-
tin have been previously described (Hocking et al., 1999). The PCR prod-
ucts were cloned into pGEX-2T (Amersham Biosciences) and transfected
into DH5  bacteria (Sambrook et al., 1989). Proteins were isolated on glu-
tathione-agarose (Amersham Biosciences) (Hocking et al., 1994). GST–III1
and GST–III1H were digested with TPCK-trypsin (Hocking et al., 1994).
III1 was separated from GST by passing the digested material over SP-
Sephadex C-25 (Amersham Biosciences). III1H was separated from GST by
retention on heparin-Sepharose (Amersham Biosciences). GST–III8–10,13
bound to heparin-Sepharose and eluted at a concentration of 0.628  
0.009 M NaCl. By comparison, the 30-kD COOH-terminal heparin-bind-
ing FN fragment elutes at 0.63 M NaCl (Ingham et al., 1990).
Antibodies
Antibodies and their sources are as follows: anti-FN III1 IgG (9D2;
Chernousov et al., 1991; a gift from Deane Mosher, University of Wiscon-
sin, Madison, WI); mouse IgG (Cappel); anticaveolin polyclonal and
LAMP-1 mAbs (BD Transduction Laboratories); anti-GST monoclonal and
polyclonal IgG (Upstate Biotechnology); anti-vinculin mAb, anti– -actin
mAb, and anti-FN polyclonal IgGs (Sigma-Aldrich).
Growth assays
Growth assays were conducted as previously described (Sottile et al.,
1998). For some experiments, recombinant FN constructs, nystatin, cyclo-
dextrin, or heparinase I (5 mU/ml; Seikagaku Corp.) were added to col-
lagen-adherent FN
 /  cells 30 min before the addition of test proteins. Hep-
arinase treatment was repeated every 24 h. After a 3- or 4-d incubation,
cells were fixed, stained with crystal violet, and the absorbance at 590 nM
was determined (Sottile et al., 1998).
Collagen gel contraction assays
Floating type I collagen gels were prepared as previously described (Hock-
ing et al., 2000). Collagen gels imbedded with cells were incubated for 20 h
and then removed from the wells and weighed. Collagen gel contraction
was measured as a decrease in gel weight (Hocking et al., 2000). Data are
reported as percent contraction: (1   weight of the test gels/weight of gels
not containing cells)   100.
Solid-phase heparin binding assay
Glutathione-coated 96-well plates (Pierce Chemical Co.) were incubated
with saturating concentrations of proteins (400 nM; 25  g/ml GST–III8–
10,13) in TBS with 0.5% Tween. Plates were then washed and incubated
with heparin–albumin–biotin followed by HRP-NeutrAvidin (Pierce Chemi-
cal Co.). Parallel plates were incubated with a polyclonal anti-GST antibody
followed by an HRP-conjugated goat anti–rabbit IgG (Bio-Rad Laboratories).
The assay was developed using 2,2 -azino-bis (3-ethylbenzthiazoline sul-
fonic acid) and the absorbance at 405 nm was measured.
Statistical analysis
Data are expressed as mean   SEM and represent one of at least three sep-
arate experiments performed in triplicate or quadruplicate. Significance
was determined using one-way analysis of variance (ANOVA) or the t test
for unpaired samples. Differences  0.05 were considered significant.
Immunofluorescence microscopy
Collagen-adherent FN
 /  cells were incubated for 5 h with 250 nM of the
GST fusion proteins. For inhibition studies, cells were pretreated for 0.5 h
with 2.5  g/ml filipin III or an equal volume of ethanol, 5 mU/ml hepari-
nase I (Seikagaku Corp.), 100 mU/ml chondroitinase ABC (Seikagaku
Corp.), 25 U/ml neuraminidase (Calbiochem-Novabiochem), or an equal
volume of DME. In other experiments, FN
 /  cells were seeded on cover-
slips coated with 10  g/ml vitronectin, grown to confluence, and then incu-
bated with 40 nM FN for 5 h. Cells were fixed with 2% paraformaldehyde
and permeabilized with 0.5% Triton X-100. Fusion proteins were visual-
ized using either anti-GST monoclonal or polyclonal antibodies. After stain-
ing, cells were examined with an Olympus BX60 microscope equipped
with epifluorescence and photographed using a Spot digital camera.
Low-density membrane fractions
Low-density membrane fractions were prepared by extraction with either
1% Triton X-100 or 0.5 M sodium carbonate, pH 11.0 (Schwab et al.,
2000). Confluent FN
 /  cells were treated with 5 mU/ml heparinase I for 1 h
before the addition of either 250 nM GST–III1H,2–4 or 40 nM FN for an
additional 5 h. Two 150-mm dishes were used for each condition. Cells
were washed with PBS and scraped into 2 ml of 1% Triton X-100 in MES-
buffered saline (MBS; 25 mM MES, 150 mM NaCl, pH 6.5). In some stud-
ies, FN
 /  cells were treated with 40 nM FN in the presence of either 25  g/
ml of 9D2 IgG or mouse IgG. After an 18-h incubation, cells were washed
and scraped into 2 ml of 0.5 M sodium carbonate, pH 11. 2 ml of cell lysate
was mixed with 2 ml of 80% sucrose in MBS. Samples were placed in a
centrifuge tube and overlaid with 4 ml each of 30 (Triton extraction) or 35%
(carbonate extraction) sucrose followed by 5% sucrose in MBS. Samples
were centrifuged at 200,000 g at 4 C for 15 h. Sequential 1-ml fractions
were collected and aliquots were analyzed by PAGE and immunoblotting.
Immunoblotting
PAGE and immunoblotting were performed as previously described
(Hocking et al., 2000). Gel samples were reduced with 2%  -mercaptoeth-
anol. Immunoblots were incubated with primary antibody in TBS-T (20
mM Tris, pH 7.6, 137 mM NaCl, 0.1% Tween 20) containing 1% BSA fol-
lowed by a goat anti–rabbit, –mouse, or –rat HRP-linked secondary anti-
body. Blots were developed using ECL (Amersham Biosciences). After de-
tection, blots were stripped by incubation with 0.2 M glycine, 0.1% SDS,
1% Tween, pH 4.0 (Miller et al., 1997). Blots were then washed, re-
blocked, and reprobed.
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